Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

BACKGROUND: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin‐23 and interleukin‐17A, respectively, and are effective in adult patients with moderate‐to‐sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983954/
https://www.ncbi.nlm.nih.gov/pubmed/32594522
http://dx.doi.org/10.1111/bjd.19341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983954/
https://www.ncbi.nlm.nih.gov/pubmed/32594522
http://dx.doi.org/10.1111/bjd.19341

Ejemplares similares